Tango Therapeutics exec exercises options, sells shares
Tango Therapeutics, Inc. President of R&D Crystal Adam reported an exercise-and-sell transaction in company stock.
Rhea-AI Filing Summary
Tango Therapeutics, Inc. President of R&D Crystal Adam reported an exercise-and-sell transaction in company stock. On May 1, 2026, she exercised 27,000 stock options at an exercise price of $5.20 per share, acquiring the same number of common shares.
That day she made two open-market sales totaling 27,000 common shares: 1,100 shares at a weighted average price of $21.9964 per share and 25,900 shares at a weighted average price of $21.1931 per share. According to a footnote, these trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on October 27, 2025.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 27,000 shares ($433K approx. pre-tax spread)
Exercise and Sale
4 txns
Insider
Crystal Adam
Role
President, R&D
Sold
27,000 shs ($573K)
Approx. gross sale proceeds
$573K
Approx. exercise cost
$140K
Approx. pre-tax spread
$433K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 27,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 27,000 | $5.20 | $140K |
| Sale | Common Stock | 25,900 | $21.1931 | $549K |
| Sale | Common Stock | 1,100 | $21.9964 | $24K |
Holdings After Transaction:
Stock Option (Right to Buy) — 368,040 contracts (Direct);
Common Stock — 115,743 shares (Direct)
Footnotes (5)
- F1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025.
- F2. Includes 3,121 shares that were acquired on November 1, 2025 pursuant to the Tango Therapeutics, Inc. 2021 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
- F3. Represents the weighted average sales price per share. The shares sold at prices ranging from $20.79 to $21.755 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F4. Represents the weighted average sales price per share. The shares sold at prices ranging from $21.80 to $22.20 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F5. This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter.
Key Figures
Shares sold (block 1): 1,100 shares
Sale price (block 1): $21.9964 per share
Shares sold (block 2): 25,900 shares
+5 more
8 metrics
Shares sold (block 1)
1,100 shares
Open-market sale on May 1, 2026 at $21.9964 weighted average
Sale price (block 1)
$21.9964 per share
Weighted average sale price for 1,100 shares on May 1, 2026
Shares sold (block 2)
25,900 shares
Open-market sale on May 1, 2026 at $21.1931 weighted average
Sale price (block 2)
$21.1931 per share
Weighted average sale price for 25,900 shares on May 1, 2026
Options exercised
27,000 shares
Common stock acquired via option exercise on May 1, 2026
Option exercise price
$5.20 per share
Strike price of stock options exercised into 27,000 shares
Remaining derivative securities
368,040 options
Derivative securities beneficially owned after the option exercise
10b5-1 plan adoption date
October 27, 2025
Date Crystal Adam’s Rule 10b5-1 trading plan was adopted
Key Terms
Rule 10b5-1 trading plan, weighted average sales price, Employee Stock Purchase Plan, Stock Option (Right to Buy), +2 more
6 terms
Rule 10b5-1 trading plan regulatory
"transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sales price financial
"Represents the weighted average sales price per share. The shares sold at prices ranging"
Employee Stock Purchase Plan financial
"acquired on November 1, 2025 pursuant to the Tango Therapeutics, Inc. 2021 Employee Stock Purchase Plan"
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
vest and become exercisable financial
"This option shall vest and become exercisable over a four-year period"
FAQ
What insider transactions did TNGX executive Crystal Adam report on May 1, 2026?
Crystal Adam reported exercising 27,000 stock options and selling 27,000 Tango Therapeutics common shares on May 1, 2026. The filing shows two open-market sales alongside the option exercise, together forming an exercise-and-sell liquidity transaction.
What was the strike price of the Tango Therapeutics stock options exercised by Crystal Adam?
The stock options exercised by Crystal Adam had an exercise price of $5.20 per share. Exercising these options converted 27,000 option rights into the same number of Tango Therapeutics common shares before the reported open-market sales.
Were the Tango Therapeutics (TNGX) insider sales by Crystal Adam part of a 10b5-1 plan?
Yes. A footnote states the transactions were effected under a Rule 10b5-1 trading plan adopted on October 27, 2025. Such pre-arranged plans automate trading to reduce the role of discretionary timing by insiders.
What happens to Crystal Adam’s Tango Therapeutics options after the reported exercise?
The filing shows 27,000 stock options were exercised into common shares, and a derivative entry lists 368,040 derivative securities remaining. That derivative line reflects the updated option balance for the broader option position after the 27,000-share exercise.
How were Crystal Adam’s Tango Therapeutics options scheduled to vest?
According to a footnote, the option vests over four years: 25% vested on February 27, 2024, with the remaining shares vesting in 36 equal monthly installments. This schedule gradually delivers exercisable options over the vesting period.
AI-generated analysis. How Rhea-AI works. Not financial advice.
